about
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis testExpression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosisExpression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal statusRelationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significanceTumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerRecommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers.Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.Who is at risk for diagnostic discrepancies? Comparison of pre- and postmortal diagnoses in 1800 patients of 3 medical decades in East and West Berlin.pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.Expression of cyclooxygenase 2 in human malignant melanoma.Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.A prognostic gene expression index in ovarian cancer - validation across different independent data sets.An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.Vascular CXCR4 expression - a novel antiangiogenic target in gastric cancer?Applying in-silico retention index and mass spectra matching for identification of unknown metabolites in accurate mass GC-TOF mass spectrometryMulticentre validation study of nucleic acids extraction from FFPE tissues.Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study.Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers.Prognostic impact of cyclooxygenase-2 in breast cancer.Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancerExpression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinomaCD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.The orphan nuclear receptors, estrogen receptor-related receptors: their role as new biomarkers in gynecological cancer.Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimizationRole of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumIntegrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany.Resistance to chemotherapy in ovarian carcinoma.Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover
P50
Q21261272-F2D3E2A3-C09B-49FE-8BE8-2E3A54EA1325Q24650522-1337F865-D0A2-42B2-819B-EBF30738641BQ24652262-CF266F31-5CA3-4BE9-955D-38704AD0C51EQ24813854-2E4649F7-E6A9-49C2-8EBD-C66BDF8BB42CQ26745446-F4098898-AE96-4028-9AF1-1D2820D5E1D1Q27304609-9170E411-2327-4035-BDCA-C5655EF6B579Q30313786-0EF67B3A-0595-4550-919D-D9AB3709B6D3Q30794842-98128899-8331-4A20-9A76-B207485304E7Q30976616-8A961F75-13E5-4A9D-B915-BF1C368CA4CDQ31062556-C19958F7-A21A-4859-B3C2-4F9ECE632615Q31153453-76C3D24D-1AD6-4CB4-BE57-290795EB7AD8Q31983368-6F9817FB-7A66-49B6-9A7C-FE4DF8542C41Q33195488-794F3DC3-3C15-4270-B2AB-B8562C27F3DDQ33415041-4340B31B-0BDE-42FF-AEE3-B1C1B53192AFQ33419209-F41268E5-E02F-4CE5-AB11-EBFA11F19302Q33519584-440FD52B-855D-4769-95FB-FA97E58C2D65Q33553482-D5DCED51-FD71-453E-A50B-FD224B47ECB4Q33934377-06FBE62F-62A1-41E5-A796-883A4CCAA13DQ34105829-13482519-5142-44B5-9E4C-9E01A76F6345Q34271033-EB3C77CF-9C1D-4D06-8937-5862CD014242Q34348061-8ADB6C26-31DF-4327-83D1-FC8964B60763Q34440998-CD1E2560-1E5F-4151-A5AB-634C51D96FD3Q34499655-F3797D6D-5EEC-498E-A744-6B1088C7B10CQ34584317-F249F21E-6894-42C9-B71B-4A9045CEB568Q35060987-E5CBA445-2D01-45AC-8F3A-D77FAC533646Q35576250-67F30567-C11A-4C7C-BD7A-C0C63B5354AEQ35653923-28509319-8586-4C8F-96DD-BBE068F45318Q35691963-CBB2C7EA-A216-4211-9AD1-49674F3772EDQ35733734-3EA66CEB-732B-4F3C-8563-3E903C52598EQ35769956-4E36D589-63B0-4B19-A53A-77208CB575D0Q35788745-A9B75EC0-F976-461B-A0A6-14ACD81153A4Q35789342-95C495DF-DF4F-445C-A965-6F83F6F6E4ECQ36450511-A346CBEC-4DB4-4C73-A9C7-476BE5429F43Q36467712-4F1514B8-175B-418A-AE73-F26D77F65966Q36498614-99F42C74-7AE1-4F19-9266-AE9C5CDC7AC6Q36557582-C039BEAB-CC7F-4190-989F-6AF7A400E87CQ36603235-5E260464-4889-4E00-99F8-302940D4AAB3Q36804777-B4A96964-35A0-4CCC-B10B-5B56E8353385Q36868767-89A0874D-7DA7-4189-AFA8-96D2F08C02AAQ36942649-98187F2A-495A-4597-B056-74EE7B0E2E05
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Carsten Denkert
@ast
Carsten Denkert
@en
Carsten Denkert
@es
Carsten Denkert
@nl
Carsten Denkert
@sl
type
label
Carsten Denkert
@ast
Carsten Denkert
@en
Carsten Denkert
@es
Carsten Denkert
@nl
Carsten Denkert
@sl
prefLabel
Carsten Denkert
@ast
Carsten Denkert
@en
Carsten Denkert
@es
Carsten Denkert
@nl
Carsten Denkert
@sl
P214
P106
P108
P21
P214
P31
P496
0000-0002-2249-0982
P7859
viaf-37705396